Cargando…
CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
Introduction. The importance of human saliva in aerosol-based transmission of SARS-CoV-2 is now widely recognized. However, little is known about the efficacy of virucidal mouthwash formulations against emergent SARS-CoV-2 variants of concern and in the presence of saliva. Hypothesis. Mouthwashes co...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Microbiology Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941951/ https://www.ncbi.nlm.nih.gov/pubmed/35180046 http://dx.doi.org/10.1099/jmm.0.001508 |
_version_ | 1784673207466328064 |
---|---|
author | Anderson, Enyia R. Patterson, Edward I. Richards, Siobhan Pitol, Ana K. Edwards, Thomas Wooding, Dominic Buist, Kate Green, Alison Mukherjee, Sayandip Hoptroff, Michael Hughes, Grant L. |
author_facet | Anderson, Enyia R. Patterson, Edward I. Richards, Siobhan Pitol, Ana K. Edwards, Thomas Wooding, Dominic Buist, Kate Green, Alison Mukherjee, Sayandip Hoptroff, Michael Hughes, Grant L. |
author_sort | Anderson, Enyia R. |
collection | PubMed |
description | Introduction. The importance of human saliva in aerosol-based transmission of SARS-CoV-2 is now widely recognized. However, little is known about the efficacy of virucidal mouthwash formulations against emergent SARS-CoV-2 variants of concern and in the presence of saliva. Hypothesis. Mouthwashes containing virucidal actives will have similar inactivation effects against multiple SARS-CoV-2 variants of concern and will retain efficacy in the presence of human saliva. Aim. To examine in vitro efficacy of mouthwash formulations to inactivate SARS-CoV-2 variants. Methodology. Inactivation of SARS-CoV-2 variants by mouthwash formulations in the presence or absence of human saliva was assayed using ASTM International Standard E1052-20 methodology. Results. Appropriately formulated mouthwashes containing 0.07 % cetylpyridinium chloride but not 0.2 % chlorhexidine completely inactivated SARS-CoV-2 (USA-WA1/2020, Alpha, Beta, Gamma, Delta) up to the limit of detection in suspension assays. Tests using USA-WA1/2020 indicates that efficacy is maintained in the presence of human saliva. Conclusions. Together these data suggest cetylpyridinium chloride-based mouthwashes are effective at inactivating SARS-CoV-2 variants. This indicates potential to reduce viral load in the oral cavity and mitigate transmission via salivary aerosols. |
format | Online Article Text |
id | pubmed-8941951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Microbiology Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-89419512022-03-29 CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva Anderson, Enyia R. Patterson, Edward I. Richards, Siobhan Pitol, Ana K. Edwards, Thomas Wooding, Dominic Buist, Kate Green, Alison Mukherjee, Sayandip Hoptroff, Michael Hughes, Grant L. J Med Microbiol Prevention, Therapy and Therapeutics Introduction. The importance of human saliva in aerosol-based transmission of SARS-CoV-2 is now widely recognized. However, little is known about the efficacy of virucidal mouthwash formulations against emergent SARS-CoV-2 variants of concern and in the presence of saliva. Hypothesis. Mouthwashes containing virucidal actives will have similar inactivation effects against multiple SARS-CoV-2 variants of concern and will retain efficacy in the presence of human saliva. Aim. To examine in vitro efficacy of mouthwash formulations to inactivate SARS-CoV-2 variants. Methodology. Inactivation of SARS-CoV-2 variants by mouthwash formulations in the presence or absence of human saliva was assayed using ASTM International Standard E1052-20 methodology. Results. Appropriately formulated mouthwashes containing 0.07 % cetylpyridinium chloride but not 0.2 % chlorhexidine completely inactivated SARS-CoV-2 (USA-WA1/2020, Alpha, Beta, Gamma, Delta) up to the limit of detection in suspension assays. Tests using USA-WA1/2020 indicates that efficacy is maintained in the presence of human saliva. Conclusions. Together these data suggest cetylpyridinium chloride-based mouthwashes are effective at inactivating SARS-CoV-2 variants. This indicates potential to reduce viral load in the oral cavity and mitigate transmission via salivary aerosols. Microbiology Society 2022-02-18 /pmc/articles/PMC8941951/ /pubmed/35180046 http://dx.doi.org/10.1099/jmm.0.001508 Text en © 2022 Unilever https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. The Microbiology Society waived the open access fees for this article. |
spellingShingle | Prevention, Therapy and Therapeutics Anderson, Enyia R. Patterson, Edward I. Richards, Siobhan Pitol, Ana K. Edwards, Thomas Wooding, Dominic Buist, Kate Green, Alison Mukherjee, Sayandip Hoptroff, Michael Hughes, Grant L. CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva |
title | CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva |
title_full | CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva |
title_fullStr | CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva |
title_full_unstemmed | CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva |
title_short | CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva |
title_sort | cpc-containing oral rinses inactivate sars-cov-2 variants and are active in the presence of human saliva |
topic | Prevention, Therapy and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941951/ https://www.ncbi.nlm.nih.gov/pubmed/35180046 http://dx.doi.org/10.1099/jmm.0.001508 |
work_keys_str_mv | AT andersonenyiar cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT pattersonedwardi cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT richardssiobhan cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT pitolanak cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT edwardsthomas cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT woodingdominic cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT buistkate cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT greenalison cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT mukherjeesayandip cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT hoptroffmichael cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva AT hughesgrantl cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva |